UCB: FINTEPLA® (fenfluramine) Oral Solution No Longer Listed as a Controlled Substance

 UCB (Euronext: UCB), a global biopharmaceutical company, today announced the U.S. Drug Enforcement Administration (DEA) has published a final rule stating that FINTEPLA oral solution is no longer subject to the Controlled Substances Act (CSA). This change is immediate.

The DEA rule means all federally controlled substance restrictions have been removed for FINTEPLA. UCB will now begin the process of updating the compendia in states where they hold licensure. Once this process is completed, in most cases prescribers will be able to write a prescription for a full year's supply versus the current limitation of six months. Additionally, the descheduling will enable prescribers to send a prescription to pharmacies electronically.

https://www.biospace.com/article/releases/ucb-announces-fintepla-fenfluramine-oral-solution-is-now-descheduled-and-is-no-longer-listed-as-a-controlled-substance/